[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 61 of about 61
17. Oh SY, Lee GW, Kim HG, Kim TH, Kim HJ, Kang JH: Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer. Chemotherapy; 2008;54(6):479-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of S-1 in combination with oxaliplatin in previously untreated patients with recurrent or inoperable biliary tract cancer.
  • RESULTS: 15 patients were enrolled: 9 patients (60%) had intrahepatic and 3 (20%) had extrahepatic cholangiocarcinoma, 2 (13.3%) had cancer of the ampulla of Vater and 1 patient had gall bladder cancer.
  • As the response rate in stage I did not justify progression to stage II (> or =2/15), this study had to be discontinued in accordance with the established protocols.

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18832821.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


18. Goodman MT, Yamamoto J: Descriptive study of gallbladder, extrahepatic bile duct, and ampullary cancers in the United States, 1997-2002. Cancer Causes Control; 2007 May;18(4):415-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive study of gallbladder, extrahepatic bile duct, and ampullary cancers in the United States, 1997-2002.
  • OBJECTIVE: Few investigations of biliary tract (gallbladder, extrahepatic bile duct, ampulla of Vater) cancers have been conducted because of the relative rarity of these malignancies.
  • RESULTS: The AAIR for gallbladder cancer among men (0.82 per 100,000) was significantly lower than the AAIR among women (1.45 per 100,000).
  • By contrast, rates for extrahepatic bile duct and ampullary cancers were significantly higher among men (0.93 per 100,000 and 0.70 per 100,000, respectively) than among women (0.61 per 100,000 and 0.45 per 100,000, respectively).
  • White men and women had significantly lower AAIRs for gallbladder cancer compared with other racial-ethnic groups, with the highest rates among Hispanics, American Indian-Alaska Natives, and Asian-Pacific Islanders.
  • Asian-Pacific Islanders and Hispanics of both sexes had the highest AAIRs for extrahepatic bile duct and ampullary cancers.
  • Ampullary tumors were more likely to be diagnosed at a localized or regional stage than were cancers of the gallbladder and extrahepatic bile duct.
  • CONCLUSIONS: This population-based study suggests distinct etiologies of anatomic subsites of biliary tract cancer and caution against analytic investigations of all biliary tract cancers combined.
  • [MeSH-major] Ampulla of Vater / pathology. Bile Duct Neoplasms / epidemiology. Gallbladder Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264972.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-67001; United States / PHS HHS / / U75/CCU515998
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


19. Albores-Saavedra J, Schwartz AM, Batich K, Henson DE: Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol; 2009 Dec 1;100(7):598-605
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program.
  • BACKGROUND: Cancers of the ampulla are unusual and morphologically heterogeneous.
  • Based on pathologic and epidemiologic characteristics of cancer of the ampulla available in SEER, important clinicopathological correlations can be made.
  • METHODS: All patients with cancer of the ampulla were identified between 1973 and 2005.
  • Demographic features, distribution of histological types, age-specific incidence rates, and 5-year survival rates according to stage and histologic type were compared.
  • RESULTS: There were 5,625 cases of ampullary cancer.
  • Ampullary cancer has been increasing since 1973.
  • Survival depends on stage, grade, and histologic type.
  • CONCLUSIONS: Prognostic factors include histologic type, grade, stage, and coexisting adenomas.
  • [MeSH-major] Ampulla of Vater / pathology. Carcinoma / mortality. Common Bile Duct Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697352.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Milsmann C, Füzesi L, Werner C, Becker H, Horstmann O: [Significance of occult lymphatic tumor spread in pancreatic cancer]. Chirurg; 2005 Nov;76(11):1064-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of occult lymphatic tumor spread in pancreatic cancer].
  • PURPOSE: The aim of this study was to determine the frequency and effect on prognosis of occult tumor cells in regional lymph nodes judged to be tumor-free in conventional histopathology of pancreatic cancer patients.
  • PATIENTS AND METHODS: Among 115 patients who underwent pancreatic resection for pancreatic (n=84) or distal common bile duct malignancy (n=12) or carcinoma of the papilla (n=19), 48 (42%) were staged pN0.
  • The occurrence of occult tumor cells was not dependent on other clinicopathological factors such as pT stage, grading, or curative resection.
  • CONCLUSION: Occult tumor cells are frequent in apparently tumor-free lymph nodes of pancreatic cancer patients and often overlooked in conventional histopathology.
  • Occult tumor cells in lymph nodes of pancreatic cancer patients could be used to stratify adjuvant therapy.
  • [MeSH-major] Ampulla of Vater / surgery. Carcinoma, Ductal / surgery. Common Bile Duct Neoplasms / surgery. Lymph Node Excision. Lymphatic Metastasis / pathology. Pancreatectomy. Pancreatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 1997 Aug;15(2):154-9 [9260200.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Dec;130(12):733-40 [15378353.001]
  • [Cites] J Hematother. 1994 Fall;3(3):165-73 [7530132.001]
  • [Cites] Acta Cytol. 1992 Mar-Apr;36(2):241-5 [1371897.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Sep;114(3):339-46 [9305185.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):870-3 [10555760.001]
  • [Cites] Pancreas. 2003 May;26(4):315-21 [12717261.001]
  • [Cites] Langenbecks Arch Surg. 1998 Apr;383(2):116-20 [9641883.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2143-9 [9815608.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):753-60 [11550144.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2668-73 [10594862.001]
  • [Cites] Am J Surg Pathol. 1999 Mar;23(3):263-7 [10078915.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1827-32 [8083707.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):993-1000; discussion 1000-1 [15570205.001]
  • [Cites] Pancreas. 1997 Nov;15(4):374-8 [9361091.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):2883-91 [3552208.001]
  • [Cites] J Clin Pathol. 1990 Mar;43(3):213-9 [1692040.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 [8380315.001]
  • [Cites] Cancer. 1993 Oct 1;72 (7):2118-23 [8104092.001]
  • [Cites] N Engl J Med. 1997 Oct 23;337(17):1188-94 [9337377.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1939-45 [10950039.001]
  • [Cites] Eur J Surg. 1996 Aug;162(8):637-42 [8891622.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1578-87 [12459624.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):1111-8 [7682761.001]
  • [Cites] Int J Oncol. 2000 Jun;16(6):1165-71 [10811991.001]
  • [Cites] Chirurg. 2001 Aug;72(8):920-6 [11554137.001]
  • [Cites] Dis Colon Rectum. 1997 Dec;40(12):1465-71 [9407986.001]
  • [Cites] Surgery. 1998 Oct;124(4):663-9 [9780986.001]
  • (PMID = 15971035.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


33. Fong D, Steurer M, Obrist P, Barbieri V, Margreiter R, Amberger A, Laimer K, Gastl G, Tzankov A, Spizzo G: Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol; 2008 Jan;61(1):31-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance.
  • Patients with ampullary cancer have a better prognosis but adjuvant therapy needs further improvement.
  • Thus, the aim of this study was to investigate Ep-CAM expression and its potential prognostic impact in pancreatic and ampullary carcinomas.
  • METHODS: Ep-CAM expression was investigated retrospectively by immunohistochemistry in paraffin-embedded primary tumour tissue samples from a series of consecutive patients with pancreatic (n = 153) and ampullary cancer (n = 34).
  • RESULTS: Ep-CAM overexpression was observed in 85 of 153 pancreatic cancer specimens (56%) and in 29 of 34 ampullary cancer samples (85%).
  • However, subgroup analyses showed that Ep-CAM overexpression correlated with shorter overall survival among patients with ampullary cancer and advanced stage pancreatic cancer.
  • Furthermore, in ampullary cancer, Ep-CAM overexpression was found to correlate with tumour stage.
  • CONCLUSIONS: Ep-CAM overexpression was detectable in the majority of cases with pancreatic and ampullary cancer.
  • [MeSH-major] Ampulla of Vater. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Common Bile Duct Neoplasms / metabolism. Pancreatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16775119.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


3
Advertisement
4. Sessa F, Furlan D, Zampatti C, Carnevali I, Franzi F, Capella C: Prognostic factors for ampullary adenocarcinomas: tumor stage, tumor histology, tumor location, immunohistochemistry and microsatellite instability. Virchows Arch; 2007 Sep;451(3):649-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for ampullary adenocarcinomas: tumor stage, tumor histology, tumor location, immunohistochemistry and microsatellite instability.
  • Prognostic factors for ampullary carcinomas (ACs) are poorly defined.
  • Factors significantly correlated with improved survival in the univariate analysis were: low stage, absence of lymph nodes metastases, negative surgical margins (R0 status), and presence of MSI.
  • In the multivariate analysis, stage was the only independent prognostic factor of survival.
  • We conclude that stage is the only independent prognostic factor of survival in the multivariate analysis, whereas histological criteria and the immunohistochemical expression of apomucins and CDX2 are helpful in the classification and understanding of the histogenesis of ACs.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater. Common Bile Duct Neoplasms / pathology. Microsatellite Instability

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1989 Aug;210(2):173-9 [2757420.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):875-82 [15223956.001]
  • [Cites] Virchows Arch. 2004 Jun;444(6):536-41 [15071739.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):508-15 [10931449.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):956-60 [11420469.001]
  • [Cites] Virchows Arch. 2001 Jan;438(1):39-48 [11213834.001]
  • [Cites] Am J Pathol. 1994 Jul;145(1):148-56 [8030745.001]
  • [Cites] Monogr Pathol. 1980;21:67-81 [6261123.001]
  • [Cites] Gastroenterology. 1996 Jan;110(1):38-44 [8536886.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1686-91 [8548242.001]
  • [Cites] Gut. 2000 Jun;46(6):842-8 [10807898.001]
  • [Cites] Lab Invest. 2003 Jul;83(7):963-71 [12861036.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Br J Surg. 1988 Aug;75(8):829-30 [3167545.001]
  • [Cites] J Surg Oncol. 2001 Feb;76(2):121-6 [11223838.001]
  • [Cites] Hum Pathol. 2006 Feb;37(2):160-7 [16426915.001]
  • [Cites] Genomics. 1995 Jul 20;28(2):206-11 [8530027.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1804-11 [12454837.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1841-7 [9815572.001]
  • [Cites] Ann Hum Genet. 1997 Sep;61(Pt 5):393-400 [9459001.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4595-7 [8062248.001]
  • [Cites] Jpn J Cancer Res. 1994 Feb;85(2):161-6 [7511574.001]
  • [Cites] Jpn J Cancer Res. 1996 Jun;87(6):631-40 [8766528.001]
  • [Cites] Pathol Int. 2003 Oct;53(10 ):667-70 [14516316.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):303-10 [12604886.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):141-9 [12548159.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):596-607 [10440687.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):359-67 [15725805.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23 ):8332-40 [16322293.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1811-8 [15774774.001]
  • (PMID = 17653761.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDX2 Transcription Factor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Mucins
  •  go-up   go-down


35. Prenzel KL, Warnecke-Eberz U, Brabender J, Baldus SE, Bollschweiler E, Gutschow CA, Drebber U, Hoelscher AH, Schneider PM: Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater. World J Gastroenterol; 2006 Jan 21;12(3):437-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential c-erbB-1 and c-erbB-2 mRNA expression in cancer of the pancreas compared with cancer of the papilla of Vater.
  • AIM: We examined quantitative mRNA expression of growth factor receptors (c-erbB-1, c-erbB-2) and the anti-apoptosis gene survivin known to be regulated in pancreatic adenocarcinomas and compared the expression pattern with that in carcinomas of the papilla of Vater.
  • METHODS: Quantitative real-time reverse transcriptase-PCR (QRT-PCR, Taqman) was performed to analyze mRNA expression levels of c-erbB-1, c-erbB-2 and survivin in normal and corresponding tumor samples of 31 pancreatic adenocarcinomas and 8 cancers of the papilla of Vater.
  • RESULTS: The overall median mRNA expression of survivin was significantly increased in both adenocarcinoma of the pancreas (P<0.01) and papilla of Vater (P<0.008) compared with uninvolved normal control tissue.
  • In pancreatic cancer, expression of c-erbB-1 was significantly decreased compared with the normal pancreatic tissue (P<0.03), whereas in the cancer of the papilla of Vater expression of c-erbB-2 was significantly downregulated (P<0.05) compared with the paired normal samples.
  • Gene expression was not associated with tumor stage, differentiation or prognosis.
  • CONCLUSION: The common anti-apoptosis gene survivin is overexpressed both in the cancer of the papilla of Vater and pancreas.
  • In contrast, the growth factor receptor genes c-erbB-1 and c-erbB-2 are differentially regulated in both tumor entities adding further evidence that pancreatic cancer is biologically different from the cancer of papilla of Vater.
  • [MeSH-major] Adenocarcinoma / metabolism. Ampulla of Vater. Common Bile Duct Neoplasms / metabolism. Pancreatic Neoplasms / metabolism. RNA, Messenger / genetics. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Dec;230(6):767-74; discussion 774-5 [10615931.001]
  • [Cites] Oncol Rep. 2005 Jun;13(6):1241-6 [15870949.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):393-8 [10666367.001]
  • [Cites] Gut. 2000 May;46(5):645-50 [10764707.001]
  • [Cites] Int J Oncol. 2000 Jul;17(1):103-6 [10853025.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):469-74 [11102889.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Lab Invest. 1999 Nov;79(11):1327-33 [10576203.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2422-32 [11331321.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):305-10 [11352303.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):677-85 [11455000.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):271-8 [11466679.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Am J Clin Oncol. 2001 Oct;24(5):496-9 [11586103.001]
  • [Cites] Surg Oncol. 2001 Jul-Aug;10(1-2):1-23 [11719025.001]
  • [Cites] Ann Surg. 2001 Dec;234(6):758-68 [11729382.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):886-92 [11953819.001]
  • [Cites] Med Electron Microsc. 2001 Dec;34(4):207-12 [11956993.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(1):1-11 [12021893.001]
  • [Cites] Stat Methods Med Res. 2002 Jun;11(3):247-74 [12094758.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1593-7 [12168842.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8581-9 [14634620.001]
  • [Cites] Pediatr Dev Pathol. 2003 Sep-Oct;6(5):392-7 [14708732.001]
  • [Cites] J Immunol. 2004 Mar 15;172(6):3922-9 [15004200.001]
  • [Cites] Hepatogastroenterology. 2004 Mar-Apr;51(56):334-7 [15086152.001]
  • [Cites] Pancreas. 2004 Jul;29(1):e1-8 [15211117.001]
  • [Cites] Surgery. 2004 Aug;136(2):443-8 [15300213.001]
  • [Cites] World J Gastroenterol. 2004 Sep 15;10(18):2759-61 [15309737.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Radiology. 1973 Nov;109(2):297-303 [4742316.001]
  • [Cites] Ann R Coll Surg Engl. 1985 May;67(3):139-43 [2988399.001]
  • [Cites] Science. 1986 Jun 27;232(4758):1644-6 [3012781.001]
  • [Cites] Br J Surg. 1987 Oct;74(10):957-61 [3664230.001]
  • [Cites] Cell. 1990 Apr 20;61(2):203-12 [2158859.001]
  • [Cites] Mol Cell Biol. 1990 Jun;10(6):2973-82 [2342466.001]
  • [Cites] J Pathol. 1990 Jul;161(3):195-200 [2202801.001]
  • [Cites] J Pathol. 1991 Feb;163(2):111-6 [1707959.001]
  • [Cites] Prog Growth Factor Res. 1992;4(1):1-24 [1355372.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):33-8 [8093983.001]
  • [Cites] Anticancer Res. 1993 May-Jun;13(3):565-9 [8317885.001]
  • [Cites] Oncology. 1993 Nov-Dec;50(6):418-25 [7901825.001]
  • [Cites] Int J Cancer. 1994 Jun 15;57(6):786-92 [8206673.001]
  • [Cites] Cell. 1994 Jul 15;78(1):5-8 [8033211.001]
  • [Cites] Br J Surg. 1995 Jan;82(1):111-5 [7881926.001]
  • [Cites] Oncology. 1995 Sep-Oct;52(5):392-6 [7637957.001]
  • [Cites] Int J Pancreatol. 1995 Feb;17(1):15-21 [8568330.001]
  • [Cites] J Urol. 1996 Jan;155(1):321-6 [7490879.001]
  • [Cites] Genome Res. 1996 Oct;6(10):986-94 [8908518.001]
  • [Cites] Genome Res. 1996 Oct;6(10):995-1001 [8908519.001]
  • [Cites] Eur J Surg Oncol. 1997 Feb;23(1):30-5 [9066744.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Anticancer Res. 1997 Sep-Oct;17(5B):3841-7 [9427790.001]
  • [Cites] Nature. 1998 Dec 10;396(6711):580-4 [9859993.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):17-31 [10638554.001]
  • (PMID = 16489645.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC4066064
  •  go-up   go-down


36. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P: The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol; 2005 Mar;31(2):164-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
  • AIM: Serum tumour markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and CA242 were investigated to evaluate the values of single and combined test in the diagnosis and prognosis of pancreatic cancer.
  • RESULTS: The sensitivity of CA19-9 alone was the highest in pancreatic cancer patients (80%), but the specificity was significantly lower than that of CEA and CA242 (P<0.01).
  • CONCLUSION: The diagnostic rate of CA19-9 in pancreatic cancer is better than that of CEA and CA242.
  • High levels of serum markers are associated with advanced stage of the disease.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / blood. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Carcinoma, Islet Cell / blood. Carcinoma, Islet Cell / diagnosis. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ampulla of Vater / metabolism. Ampulla of Vater / pathology. Bile Duct Neoplasms / blood. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic / metabolism. Bile Ducts, Extrahepatic / pathology. Bilirubin / blood. Cholangiocarcinoma / blood. Cholangiocarcinoma / diagnosis. Cholangiocarcinoma / surgery. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pancreaticoduodenectomy. Prognosis. Sensitivity and Specificity. Statistics as Topic. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15698733.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA 242 antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


37. Hsu HP, Shan YS, Hsieh YH, Yang TM, Lin PW: Predictors of recurrence after pancreaticoduodenectomy in ampullary cancer: comparison between non-, early and late recurrence. J Formos Med Assoc; 2007 Jun;106(6):432-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of recurrence after pancreaticoduodenectomy in ampullary cancer: comparison between non-, early and late recurrence.
  • BACKGROUND/PURPOSE: Ampullary cancer is one of the periampullary cancers with a better prognosis, but relapse still occurs early in some patients.
  • METHODS: Between January 1989 and March 2006, information was gathered on a total of 127 patients undergoing pancreaticoduodenectomy with regional lymphadenectomy for ampullary cancer at National Cheng Kung University Hospital and Tainan Municipal Hospital.
  • The early and late recurrence patients had higher levels of microscopically (R1) or macroscopically (R2) positive margin of resection and more advanced disease (advanced tumor stage, numbers of lymph nodes involved, lymph node status, pancreatic invasion and TNM stage) than the non-recurrence group.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17588836.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


38. Woo SM, Ryu JK, Lee SH, Yoo JW, Park JK, Kim YT, Jang JY, Kim SW, Kang GH, Yoon YB: Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma. Ann Surg Oncol; 2007 Nov;14(11):3195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma.
  • BACKGROUND: Ampullary carcinoma is often considered to have a better prognosis than distal extrahepatic cholangiocarcinoma.
  • METHODS: Clinicopathologic factors and the long-term outcomes of 163 patients with ampullary carcinoma after radical resection were retrospectively evaluated and compared with those of 91 patients with distal extrahepatic cholangiocarcinoma.
  • RESULTS: Among the 163 ampullary carcinomas, T1 stage, well-differentiated tumors and perineural invasion were 45 (28%), 73 (45%), and 23 (14%), respectively, whereas, only five (6%) were T1 stage, 15 (17%) were well differentiated, and 63 (69%) showed perineural invasion (p < 0.001, for all) in distal extrahepatic cholangiocarcinomas.
  • More patients with distal extrahepatic cholangiocarcinoma had liver metastasis than ampullary carcinoma (24% vs. 10%, p = 0.004).
  • Multivariate analysis identified venous invasion and perineural invasion as risk factors for recurrence of ampullary carcinoma after radical resection.
  • Overall five-year survival of patients with ampullary cancer was higher than that of patients with distal extrahepatic cholangiocarcinoma (68% vs. 54%; p = 0.033).
  • CONCLUSION: Earlier diagnosis and the less frequent occurrence of pathological factors associated with tumor invasiveness in ampullary carcinoma than in distal extrahepatic cholangiocarcinoma may explain its association with a better prognosis.
  • [MeSH-major] Ampulla of Vater / pathology. Bile Ducts, Extrahepatic / pathology. Cholangiocarcinoma / pathology. Common Bile Duct Neoplasms / pathology. Neoplasm Recurrence, Local / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710498.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. O'Connell JB, Maggard MA, Manunga J Jr, Tomlinson JS, Reber HA, Ko CY, Hines OJ: Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol; 2008 Jul;15(7):1820-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after resection of ampullary carcinoma: a national population-based study.
  • BACKGROUND: Ampullary cancer is the second most common periampullary cancer, with a resection and survival rate more favorable than that for pancreatic cancer.
  • Our objective was to complete a population-based analysis of patients undergoing resection for ampullary carcinoma and compare it with outcomes in the published literature.
  • METHODS: Patients diagnosed with ampullary cancer reported in the Surveillance, Epidemiology, and End Results program (1988-2003) were collected.
  • Primary outcome was survival (5-year), and secondary outcome was stage at presentation.
  • RESULTS: Of the 3292 ampullary cancer patients, 1301 (40%) underwent resection.
  • Thirty-seven percent presented with stage I tumors.
  • The cancer registry data showed less early stage disease, higher perioperative mortality, and lower 5-year survival compared with published reports.
  • CONCLUSIONS: This is the largest population-based analysis of ampullary carcinoma.
  • Resection rates and survival at the national level are lower, in general, compared with cancer center reports, which may have implications for regionalizing these procedures.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Ampulla of Vater / surgery. Common Bile Duct Neoplasms / mortality. Common Bile Duct Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2008 Jul;15(7):1813-4 [18425553.001]
  • (PMID = 18369675.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Qiao QL, Zhao YG, Ye ML, Yang YM, Zhao JX, Huang YT, Wan YL: Carcinoma of the ampulla of Vater: factors influencing long-term survival of 127 patients with resection. World J Surg; 2007 Jan;31(1):137-43; discussion 144-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the ampulla of Vater: factors influencing long-term survival of 127 patients with resection.
  • INTRODUCTION: The prognosis for patients with carcinoma of the ampulla of Vater is improved relative to other periampullary neoplasms.
  • Identification of independent prognostic factors in ampullary carcinomas has been limited by the small number of tumors resected.
  • The aim of the present study was to determine the clinicopathologic factors that influence long-term survival in patients with resected ampullary carcinoma.
  • METHODS: Clinicopathologic data were retrospectively reviewed for patients with ampullary carcinomas radically resected between March 1987 and September 2002.
  • Ampullary carcinomas were radically resected in 127 patients either by pancreaticoduodenectomy (n = 124) or local resection (n = 3).
  • Factors that significantly influenced survival were lymph node status (P < 0.001), depth of tumor infiltration (P = 0.029), and TNM stage (P < 0.001) on univariate analysis.
  • CONCLUSIONS: Carcinoma of the ampulla of Vater has a higher resectability rate and a much better survival rate than pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / mortality. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1996 Apr;131(4):366-71 [8615720.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Ann Surg. 1997 May;225(5):590-9; discussion 599-600 [9193186.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):621-7 [8916877.001]
  • [Cites] World J Surg. 1996 Jul-Aug;20(6):707-12 [8662157.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):355-66; discussion 366-8 [12192322.001]
  • [Cites] Arch Surg. 1993 May;128(5):515-20 [8098205.001]
  • [Cites] World J Surg. 1997 May;21(4):379-83 [9143568.001]
  • [Cites] Am Surg. 1999 Nov;65(11):1043-8 [10551754.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):33-8 [8093983.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1686-91 [8548242.001]
  • [Cites] Surgery. 1995 Mar;117(3):247-53 [7878528.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1176-83 [14654474.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):506-15 [3791159.001]
  • [Cites] Arch Surg. 2003 Sep;138(9):941-8; discussion 948-50 [12963649.001]
  • [Cites] World J Surg. 2005 Apr;29(4):519-23 [15770375.001]
  • [Cites] Surgery. 1986 Oct;100(4):716-23 [3764694.001]
  • [Cites] Arch Surg. 2005 Jun;140(6):529-32; discussion 532-3 [15967899.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):353-7 [1998478.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):65-9 [11146780.001]
  • [Cites] Ann Surg. 1977 Jan;185(1):52-7 [831636.001]
  • [Cites] World J Surg. 2005 Apr;29(4):513-8 [15776300.001]
  • [Cites] Br J Surg. 1994 May;81(5):668-71 [7913860.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1693-6 [8548244.001]
  • [Cites] Ann Surg. 1975 May;181(5):534-40 [1130871.001]
  • (PMID = 17171495.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Shan Y, Zhao DB, Che X, Wang JX, Shao YF, Zhao P: [Clinical significance of solitary lymph node metastasis in carcinoma of the ampulla of Vater]. Zhonghua Zhong Liu Za Zhi; 2006 Sep;28(9):694-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of solitary lymph node metastasis in carcinoma of the ampulla of Vater].
  • OBJECTIVE: To investigate the rule of distribution of solitary lymph node metastasis and its relation with clinico-pathologic factors in carcinoma of ampulla of Vater.
  • METHODS: The data of 26 patients who were discovered to have solitary lymph node metastasis, from 152 patients with carcinoma of the ampulla of Vater who had received pancreatoduodenectomy were retrospectively reviewed.
  • RESULTS: Of these 152 patients with carcinoma of ampulla of Vater, 47(30.
  • 003) , T stage(P = 0.
  • Sentinel lymph node assessment may be helpful to determine the extent of lymph node dissection for carcinoma of the ampulla of Vater.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater. Common Bile Duct Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17274378.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


42. Alibegov RA, Prokhorenko TI, Sergeev OA, Khlusov AN: [The long term results and survival prognostic factors of surgical treatment ampulla Vateri cancer]. Khirurgiia (Mosk); 2008;(4):27-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The long term results and survival prognostic factors of surgical treatment ampulla Vateri cancer].
  • Results of radical operative treatment of 21 patients with ampulla Vateri cancer are presented.
  • Factors having prognostic value for survival rate are the stage of disease, metastatic regional spread, tumor invasion in a head of a pancreas, microscopic picture of a pancreatitis in a phase of acute condition.
  • However, the only independent factor of the prognosis for a disease is the stage of neoplastic process.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / mortality. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454104.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


43. Tsujioka T, Wada H, Yata K, Kondo T, Suemori S, Tokunaga H, Ohmori K, Kubo Y, Nakanishi H, Mikami M, Haruma K, Sadahira Y, Sugihara T: [Clinical analysis of eight patients with primary follicular lymphoma in the duodenum]. Rinsho Ketsueki; 2007 Feb;48(2):134-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients were in clinical stage I EA.
  • Gastroendoscopic findings showed multiple whitish granules around the ampulla of Vater in all patients.
  • Seven patients are currently alive, and one died of uterine cancer.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17370641.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


44. Alibegov RA, Prokhorenko TI, Sergeev OA, Khlusov AN: [Clinico-morphological factors of prognosis in cancer of the major duodenum papilla]. Vestn Khir Im I I Grek; 2008;167(2):26-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinico-morphological factors of prognosis in cancer of the major duodenum papilla].
  • Long-term results of radical operative treatment of 19 patients with cancer of the major duodenal papilla were analyzed.
  • The data of a univariant analysis show that favorable factors of survival are the early stage of the tumor disease, the absence of metastatic lesion of the regional lymph nodes, tumor invasion into the pancreas and a microscopic picture of pancreatitis in the stage of exacerbation.
  • But the multivariant analysis showed that the stage of the disease is an independent factor of prognosis.
  • [MeSH-major] Adenocarcinoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Pancreaticoduodenectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18522181.001).
  • [ISSN] 0042-4625
  • [Journal-full-title] Vestnik khirurgii imeni I. I. Grekova
  • [ISO-abbreviation] Vestn. Khir. Im. I. I. Grek.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


45. Tien YW, Yeh CC, Wang SP, Hu RH, Lee PH: Is blind pancreaticoduodenectomy justified for patients with ampullary neoplasms? J Gastrointest Surg; 2009 Sep;13(9):1666-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is blind pancreaticoduodenectomy justified for patients with ampullary neoplasms?
  • Our aim in this study was to determine whether blind-PD is also justified for ampullary neoplasms.
  • METHODS: We retrospectively reviewed the records of all patients with presumed resectable ampullary neoplasms treated at the National Taiwan University Hospital from 1998 to 2008.
  • CONCLUSIONS: Our data support a selective use of blind-PD because (1) a significant portion (65%) of benign ampullary neoplasms can be safely and effectively treated by AMP, (2) blind-PD does not treat ampullary cancer at earlier stage, and (3) blind-PD is associated with significantly more complications and significantly longer hospital stay than AMP.
  • However, blind-PD is strongly recommended for patients with large ampullary neoplasms (>3 cm in diameter), with jaundice, or with malignant endoscopic appearance.
  • [MeSH-major] Ampulla of Vater / pathology. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Pancreaticoduodenectomy / methods

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1996 Apr;131(4):366-71 [8615720.001]
  • [Cites] World J Surg. 1999 Feb;23(2):158-62; discussion 162-3 [9880425.001]
  • [Cites] Curr Opin Gastroenterol. 2008 Sep;24(5):617-22 [19122504.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):955-6 [16228813.001]
  • [Cites] Br J Surg. 1997 Jul;84(7):948-51 [9240132.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):161-7 [2471581.001]
  • [Cites] South Med J. 1989 Jul;82(7):917-20 [2665132.001]
  • [Cites] Gastrointest Endosc. 2002 Aug;56(2):239-43 [12145603.001]
  • [Cites] J Gastrointest Surg. 2006 Sep-Oct;10(8):1140-3 [16966033.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):32-41 [12704445.001]
  • [Cites] Ann Chir. 2004 Mar;129(2):73-8 [15050176.001]
  • [Cites] Ann Surg Oncol. 2005 Dec;12(12):971-80 [16244798.001]
  • [Cites] Am Surg. 2004 Jan;70(1):6-10; discussion 11-2 [14964538.001]
  • [Cites] Am Surg. 1990 Apr;56(4):214-7 [2194412.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1300-6 [16332486.001]
  • [Cites] Ann Surg Oncol. 2008 Jul;15(7):1855-61 [18415651.001]
  • [Cites] Pancreas. 1995 Oct;11(3):283-8 [8577683.001]
  • [Cites] Endoscopy. 2003 May;35(5):402-6 [12701011.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):225-32 [14745396.001]
  • [Cites] Surgery. 2000 Jun;127(6):628-33 [10840357.001]
  • [Cites] Ann Surg. 1986 Mar;203(3):301-6 [3954483.001]
  • [Cites] Am J Surg Pathol. 1991 Dec;15(12):1188-96 [1746684.001]
  • [Cites] Arch Surg. 1999 May;134(5):526-32 [10323425.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):92-100 [15973106.001]
  • [Cites] Gastrointest Endosc. 1993 Mar-Apr;39(2):127-31 [8495831.001]
  • [Cites] Gastrointest Endosc. 1990 Nov-Dec;36(6):588-92 [2279648.001]
  • [Cites] Endoscopy. 2005 May;37(5):444-8 [15844023.001]
  • (PMID = 19557483.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Spyropoulou D, Vassiliou V, Tzelepi V, Kardari M, Tsamandas AC, Kardamakis D: Metastatic adenocarcinoma of parotid gland originating from the ampulla of vater: case report and review of the literature. J Gastrointest Cancer; 2007;38(2-4):95-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of parotid gland originating from the ampulla of vater: case report and review of the literature.
  • AIM: To report a rare case of metastasis from an adenocarcinoma of the ampulla of Vater to the parotid gland.
  • PATIENTS AND METHODS: In February 2004, a 61-year-old male underwent Whipple surgery due to a grade II adenocarcinoma of the ampulla of Vater (stage IB:pT2N0M0).
  • Fine needle aspiration showed that the infiltrating mass was due to an adenocarcinoma of the ampulla of Vater.
  • CONCLUSIONS: Metastasis of adenocarcinoma of the ampulla of Vater to the parotid gland has not to our knowledge been previously reported.
  • [MeSH-major] Adenocarcinoma / secondary. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology. Parotid Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Arch Surg. 1963 Nov;87:757-64 [14058839.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(5):301-9 [15549428.001]
  • [Cites] Surg Gynecol Obstet. 1993 Jan;176(1):33-8 [8093983.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 2005 Feb;122(1):18-20 [15851941.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Dec;135(6):844-8 [17141071.001]
  • [Cites] Dis Colon Rectum. 1985 Mar;28(3):190-2 [3971828.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1176-83 [14654474.001]
  • [Cites] Otolaryngol Pol. 2005;59(4):547-52 [16273860.001]
  • [Cites] J Surg Oncol. 1976;8(2):183-90 [1263521.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1996 Feb;8(2):139-44 [8723418.001]
  • [Cites] Diagn Cytopathol. 2006 Aug;34(8):580-4 [16850487.001]
  • [Cites] J Surg Oncol. 2007 Mar 15;95(4):286-90 [17326125.001]
  • [Cites] Int J Urol. 2004 Oct;11(10):894-6 [15479296.001]
  • [Cites] Australas Radiol. 2004 Mar;48(1):88-92 [15027931.001]
  • [Cites] Acta Otorrinolaringol Esp. 2006 Jan;57(1):47-50 [16503033.001]
  • [Cites] Clin Transl Oncol. 2007 Apr;9(4):264-5 [17462982.001]
  • [Cites] Laryngoscope. 2003 Jun;113(6):1070-5 [12782825.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2007;69(1):51-6 [17085953.001]
  • (PMID = 19016351.001).
  • [ISSN] 1941-6628
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


47. Kim K, Chie EK, Jang JY, Kim SW, Oh DY, Im SA, Kim TY, Bang YJ, Ha SW: Role of adjuvant chemoradiotherapy for ampulla of Vater cancer. Int J Radiat Oncol Biol Phys; 2009 Oct 1;75(2):436-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of adjuvant chemoradiotherapy for ampulla of Vater cancer.
  • PURPOSE: To evaluate the role of adjuvant chemoradiotherapy for ampulla of Vater cancer.
  • METHODS AND MATERIALS: Between January 1991 and December 2002, 118 patients with ampulla of Vater cancer underwent en bloc resection.
  • When age, type of operation, T stage, N stage, histologic differentiation, and the use of adjuvant chemoradiotherapy were incorporated into the Cox proportional hazard model, there was an improvement in the locoregional relapse-free survival rate (p = 0.0050) and a trend toward a longer overall survival (p = 0.0762) associated with the use of adjuvant chemoradiotherapy.
  • CONCLUSIONS: Adjuvant chemoradiotherapy may enhance locoregional control and overall survival in patients with ampulla of Vater cancer after curative resection, especially in those with nodal involvement.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / radiotherapy

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394162.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


48. Franko J, Krasinskas AM, Nikiforova MN, Zarnescu NO, Lee KK, Hughes SJ, Bartlett DL, Zeh HJ 3rd, Moser AJ: Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma. J Gastrointest Surg; 2008 Oct;12(10):1664-72; discussion 1672-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: American Joint Committee on Cancer (AJCC) staging for pancreatic adenocarcinoma is a validated predictor of prognosis but insufficiently discriminates postresection survival.
  • METHODS: Resected pancreatic ductal and ampullary adenocarcinomas (n = 50) were analyzed for loss of heterozygosity (LOH) at 15 markers including 5q(APC), 6q(TBSP2), 9p(p16), 10q(PTEN), 12q(MDM2), 17p(TP53), and 18q(DCC/SMAD4).
  • AJCC stage was: Ia/b (3), IIa (16), IIb (31).
  • Stage, nodal and margin status were not predictive of survival.
  • CONCLUSION: LOH and KRAS mutations indicate aggressive tumor biology and correlate strongly with survival in resected pancreatic ductal and ampullary carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Ampulla of Vater. Common Bile Duct Neoplasms / genetics. Loss of Heterozygosity. Pancreatic Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / surgery. Female. Genes, Tumor Suppressor. Humans. Male. Middle Aged. Mutation. Pancreatectomy. Pilot Projects. Predictive Value of Tests. Prognosis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins p21(ras). Retrospective Studies. Survival Analysis. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2006 Jul;244(1):10-5 [16794383.001]
  • [Cites] Pancreas. 1996 May;12(4):373-80 [8740405.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3126-30 [9242437.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7529-35 [16234519.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14888-93 [10611308.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):2080-5 [10950061.001]
  • [Cites] Development. 2007 Aug;134(15):2719-25 [17596282.001]
  • [Cites] J Gastrointest Surg. 2004 Dec;8(8):935-49; discussion 949-50 [15585381.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):587-95 [17290067.001]
  • [Cites] Arch Surg. 2003 Apr;138(4):427-3; discussion 433-4 [12686529.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):355-66; discussion 366-8 [12192322.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):15-29 [10721693.001]
  • [Cites] World J Gastroenterol. 2005 Apr 14;11(14 ):2162-5 [15810085.001]
  • [Cites] Breast Cancer Res. 2006;8(3):R25 [16737553.001]
  • [Cites] Annu Rev Cell Biol. 1991;7:601-32 [1667084.001]
  • [Cites] Science. 1998 May 15;280(5366):1036-7 [9616081.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4670-5 [7553647.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):871-5 [14871814.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jun;103(2):197-208 [17039265.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):488-99 [11505392.001]
  • [Cites] Oncogene. 2007 Jul 19;26(33):4850-62 [17297450.001]
  • [Cites] J Gastrointest Surg. 2004 Nov;8(7):775-84; discussion 784 [15531230.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8121-30 [17804724.001]
  • [Cites] Liver Transpl. 2003 Jul;9(7):664-71 [12827550.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):738-44 [17580363.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):235-41 [16397047.001]
  • [Cites] Science. 1987 Jun 26;236(4809):1657-61 [2885916.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):326-32 [10023699.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10 ):3933-8 [18316739.001]
  • [Cites] Mol Cell. 2001 Jul;8(1):85-94 [11511362.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):2969-72 [10955772.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1372-81 [15812554.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):383-91 [9408755.001]
  • [Cites] Ann Intern Med. 2008 Mar 4;148(5):358-69 [18252678.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):5044-52 [14581380.001]
  • [Cites] Surgery. 1973 Feb;73(2):307-20 [4265314.001]
  • [Cites] Mol Cancer. 2003 Jan 07;2:7 [12537585.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):545-52 [18199551.001]
  • [Cites] Ann Surg. 2007 Aug;246(2):173-80 [17667493.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):293-8 [15273554.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Ann Surg. 1996 Feb;223(2):147-53 [8597508.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):2123-33 [10854233.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2890-6 [12019169.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Arch Surg. 2008 Jan;143(1):75-83; discussion 83 [18209156.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):701-6 [18027062.001]
  • [Cites] J Gastrointest Surg. 2006 Mar;10(3):347-56 [16504879.001]
  • [Cites] Curr Opin Cell Biol. 1998 Apr;10(2):262-7 [9561851.001]
  • [Cites] Cancer Biol Ther. 2002 Nov-Dec;1(6):607-13 [12642681.001]
  • [Cites] Ann Surg Oncol. 2006 Sep;13(9):1189-200 [16955385.001]
  • [Cites] Blood. 1995 Aug 1;86(3):841-54 [7620180.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9624-9 [10944227.001]
  • [Cites] World J Surg. 1997 Feb;21(2):195-200 [8995078.001]
  • [Cites] World J Gastroenterol. 2007 Jul 21;13(27):3714-20 [17659731.001]
  • [Cites] Cell. 1988 May 20;53(4):549-54 [2453289.001]
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1196-206 [11309634.001]
  • [Cites] Surgery. 2007 May;141(5):610-8 [17462460.001]
  • (PMID = 18677542.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


49. van Oost FJ, Luiten EJ, van de Poll-Franse LV, Coebergh JW, van den Eijnden-van Raaij AJ: Outcome of surgical treatment of pancreatic, peri-ampullary and ampullary cancer diagnosed in the south of The Netherlands: a cancer registry based study. Eur J Surg Oncol; 2006 Jun;32(5):548-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of surgical treatment of pancreatic, peri-ampullary and ampullary cancer diagnosed in the south of The Netherlands: a cancer registry based study.
  • AIMS: To gain insight into the quality of pancreatic cancer surgery in 10 low-volume (median sized) hospitals, each serving 150,000-250,000 people, in the Comprehensive Cancer Centre South (CCCS) area and of referred patients to academic centres to determine the need for further regionalization.
  • METHOD: The population-based Eindhoven Cancer Registry was used to select all patients in the CCCS area with pancreatic, peri-ampullary and ampullary cancer diagnosed between January 1, 1995 and April 30, 2000 (N = 1130).
  • RESULTS: For all pancreatic carcinoma resections, the 3-month survival rate was 82%, varying from 95% for referred patients to 76% for patients treated within the region (p = 0.014).
  • Surgically treated patients who were referred to university hospitals outside the CCCS area were younger, more often male, more often diagnosed with pTNM stage III, exhibited less comorbidity and had a higher socio-economic status than patients surgically treated within the region.
  • [MeSH-major] Ampulla of Vater / surgery. Carcinoma / surgery. Common Bile Duct Neoplasms / surgery. Pancreatic Neoplasms / surgery. Registries

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16569495.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


50. Yoon SM, Kim MH, Kim MJ, Jang SJ, Lee TY, Kwon S, Oh HC, Lee SS, Seo DW, Lee SK: Focal early stage cancer in ampullary adenoma: surgery or endoscopic papillectomy? Gastrointest Endosc; 2007 Oct;66(4):701-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal early stage cancer in ampullary adenoma: surgery or endoscopic papillectomy?
  • BACKGROUND: Recently, the evidence has been accumulating that endoscopic resection may be curative in treating ampullary adenoma that contains high-grade intraepithelial neoplasia/in situ tumor (HGIN/Tis).
  • However, there are only anecdotal reports of endoscopic management of "focal" T1 ampullary cancer (T1 cancer), and radical surgery is still considered the only accepted treatment modality.
  • OBJECTIVE: To assess the possibility of endoscopic papillectomy as an alternative to radical surgery for the treatment of ampullary adenoma with HGIN/Tis or focal T1 cancer.
  • PATIENTS: Twenty-three patients who had HGIN/Tis or focal T1 cancer in ampullary adenoma resected by endoscopic papillectomy and 60 patients who initially underwent radical surgery for HGIN/Tis or T1 cancer of the ampulla of Vater.
  • INTERVENTIONS: Review of medical records and analysis of surgically or endoscopically resected specimens of ampullary tumors.
  • RESULTS: Patients with HGIN/Tis of the ampulla of Vater had no lymphovascular invasion or lymph-node metastasis, and there were no occurrences of cancer or deaths during a mean (standard error [+/-SE]) 27.1 +/- 5.9 months after endoscopic papillectomy.
  • T1 cancer was shown to have lymphovascular invasion and/or lymph-node metastasis in 10.7% and duct mucosal involvement in another 17.9%.
  • Among them, patients with focal T1 cancer showed no lymphovascular invasion or lymph-node metastasis and no ductal involvement, and none of the patients who underwent endoscopic papillectomy alone had cancer recurrence or disease-related death for mean (+/-SE) 32.2 +/- 6.7 months.
  • CONCLUSIONS: Endoscopic papillectomy may be a curative treatment for ampullary adenoma with HGIN/Tis and should also be considered as an alternative to surgery in focal T1 cancer in ampullary adenoma.
  • [MeSH-major] Adenoma / surgery. Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Endoscopy, Gastrointestinal / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17905011.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Lu ZC, Guo JM, Zhang YL, Tian PL, Zhang L, Yu JP, Bao XY: [Comparison of endoscopic ultrasonography with computer-assisted tomography in the determination of preoperative stage and resectability of pancreatic and ampullary cancers]. Zhonghua Zhong Liu Za Zhi; 2006 Jun;28(6):441-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of endoscopic ultrasonography with computer-assisted tomography in the determination of preoperative stage and resectability of pancreatic and ampullary cancers].
  • OBJECTIVE: To study and compare the accuracy and sensitivity of endoscopic ultrasonography (EUS) and CT scaning in determination of preoperative stage and vascular invasion by pancreatic and ampullary cancers.
  • METHODS: Fourty-two pancreatic cancer patients and 18 ampullary cancer patients were studied.
  • The structures of each part of pancreatic head and ampullary together with surrounding vessels were scanned.
  • 1996 to May 2004, a total of 42 pancreatic cancer patients and 18 ampullary cancer patients were examined by EUS.
  • The results of stage and vascular invasion determined by EUS in this series were as following; pancreatic cancer group (n = 42): accuracy in T2-4 stage was 100.0% (5/5), 75.0% (9/12) and 48.0% (12/25), respectively; ampullary cancer group (n = 18): T1-4 stage was 75.0% (3/4), 66.7% (2/3), 75.0% (6/8) and 33.3% (1/3), respectively; the accuracy in N stage: P-group: 80.0% in N1 (4/5), 90.0% in N0 (9/10); A-group: 50.0% in N1 (3/6), 91.0% in N0 (10/11).
  • CONCLUSION: Endoscopic ultrosonography being one of the best image examinations to determine the stage and vascular invasion for pancreatic and ampullary cancer paitients is able to detect small pancreatic or ampullary cancer less than 2.0 cm in diameter due to its high resolution; but can not detect the secondary multiple distal metastases such as spread into the liver, peritonium or hepatoduodenal ligament, etc. due to its ultrasound depth limitation.
  • [MeSH-major] Ampulla of Vater / ultrasonography. Common Bile Duct Neoplasms / ultrasonography. Endosonography. Pancreas / ultrasonography. Pancreatic Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152491.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


52. Lee SY, Jang KT, Lee KT, Lee JK, Choi SH, Heo JS, Paik SW, Rhee JC: Can endoscopic resection be applied for early stage ampulla of Vater cancer? Gastrointest Endosc; 2006 May;63(6):783-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can endoscopic resection be applied for early stage ampulla of Vater cancer?
  • BACKGROUND: Although endoscopic resection can provide a wide tumor resection with a negative resection margin, it is not yet recommended as a curative therapy for ampulla of Vater cancer.
  • METHODS: To investigate the microinvasion rate and the diagnostic accuracy of endoscopic biopsy to properly judge the safety of endoscopic resection for ampulla of Vater cancer.
  • PATIENTS: One hundred fifty-nine patients who were finally diagnosed with ampulla of Vater cancer after curative surgical resection.
  • For the 36 early stage (Tis or T1) cancers, we surveyed the presence of microlymphovascular invasion, gross appearance (intra-ampullary type, periampullary type, or mixed type), and pathologic subtype (intestinal type or pancreaticobiliary type).
  • MAIN OUTCOME MEASUREMENTS: Presence of microinvasion in early staged ampulla of Vater cancer.
  • CONCLUSIONS: Although endoscopic resection improves the low predictability of endoscopic biopsy, surgical resection should be performed for the T1 stage ampulla of Vater cancer because of the high lymphovascular invasion rate.
  • [MeSH-major] Ampulla of Vater. Common Bile Duct Neoplasms / surgery. Sphincter of Oddi. Sphincterotomy, Endoscopic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2006 May;63(6):789-91 [16650539.001]
  • (PMID = 16650538.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Katsinelos P, Kountouras J, Chatzimavroudis G, Zavos C, Pilpilidis I, Fasoulas K, Paroutoglou G: Wireless capsule endoscopy in detecting small-intestinal polyps in familial adenomatous polyposis. World J Gastroenterol; 2009 Dec 28;15(48):6075-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients' age, sex, years of observation after surgery, type of surgery, duodenal polyps and colorectal cancer at surgery were analyzed.
  • The Spigelman stage of duodenal polyposis was associated with the presence of jejunal and ileal polyps.
  • Identification of the ampulla of Vater was not achieved with WCE.

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Abdom Imaging. 2009 Jul;34(4):452-8 [18575929.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):911-9 [18561922.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1127-35 [11677205.001]
  • [Cites] Gastroenterology. 2001 Nov;121(5):1246-8 [11677220.001]
  • [Cites] Gut. 2002 May;50(5):636-41 [11950808.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2003 Apr;17(2):237-58 [12676117.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1698-707 [12721244.001]
  • [Cites] Ann Surg. 1970 Feb;171(2):300-2 [5413466.001]
  • [Cites] Nature. 1987 Aug 13-19;328(6131):614-6 [3039373.001]
  • [Cites] Lancet. 1989 Sep 30;2(8666):783-5 [2571019.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Science. 1991 Aug 9;253(5020):661-5 [1651562.001]
  • [Cites] Gastrointest Endosc. 1999 Mar;49(3 Pt 1):358-64 [10049420.001]
  • [Cites] Endoscopy. 2004 Dec;36(12):1054-9 [15578294.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):27-37 [15654777.001]
  • [Cites] Gastrointest Endosc. 2005 May;61(6):721-5 [15855978.001]
  • [Cites] Am J Gastroenterol. 2005 Jul;100(7):1498-502 [15984971.001]
  • [Cites] Gastrointest Endosc. 2005 Sep;62(3):448-52 [16111973.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2006 Apr;16(2):329-36 [16644461.001]
  • [Cites] Gastrointest Endosc. 2006 Oct;64(4):530-7 [16996344.001]
  • [Cites] Gastrointest Endosc. 2008 Jan;67(1):61-7 [18155426.001]
  • [Cites] World J Gastroenterol. 2008 Sep 14;14(34):5245-53 [18785274.001]
  • [Cites] Gut. 2001 Apr;48(4):515-21 [11247896.001]
  • (PMID = 20027680.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2797664
  •  go-up   go-down


54. Bezrodnyĭ BH, Korotkyĭ VM, Khomenko DI: [Performance of reconstruction stage of the pancreatic-duodenal resection for the cancer of the pancreatic head and periampullary zone]. Klin Khir; 2009 Jul-Aug;(7-8):11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Performance of reconstruction stage of the pancreatic-duodenal resection for the cancer of the pancreatic head and periampullary zone].

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20218357.001).
  • [ISSN] 0023-2130
  • [Journal-full-title] Klinichna khirurhiia
  • [ISO-abbreviation] Klin Khir
  • [Language] UKR
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


55. Shin JA, An M, Choi JI, Kim SH, Lee WJ, Park SJ, Park JW, Hong EK: [A case of hepatectomy for liver metastasis after pancreatoduodenectomy for carcinoma of ampulla of Vater]. Korean J Gastroenterol; 2006 Dec;48(6):434-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of hepatectomy for liver metastasis after pancreatoduodenectomy for carcinoma of ampulla of Vater].
  • After curative resection of carcinoma of ampulla of Vater, 5-year survival rate has been reported ranging from 40% to 60%.
  • There have been few reports on long-term survivors after hepatectomy for metastatic liver tumors from carcinoma of ampulla of Vater.
  • We report a 42 year-old female patient with solitary hepatic metastasis from carcinoma of ampulla of Vater, which was successfully treated by hepatectomy 69 months after curative Whipple's operation.
  • Histologic examination of the resected specimen had revealed stage IB moderately-differentiated, intestinal type adenocarcinoma (T2N0M0).
  • Histologic study confirmed the presence of metastatic liver tumor from carcinoma of ampulla of Vater.
  • [MeSH-major] Ampulla of Vater. Carcinoma / diagnosis. Carcinoma / surgery. Common Bile Duct Neoplasms / pathology. Hepatectomy. Liver Neoplasms / diagnosis. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189929.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


56. Yamashita Y, Ito K, Fujita N, Noda Y, Kobayashi G, Obana T, Horaguchi J, Kato Y, Koshita S, Kanno Y, Ogawa T, Kurose A, Sawai T: A case of early carcinoma of the papilla of Vater confined to the mucosa and continuative epithelium of glands in Oddi's sphincter (m-God) treated by endoscopic papillectomy. Intern Med; 2010;49(22):2447-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of early carcinoma of the papilla of Vater confined to the mucosa and continuative epithelium of glands in Oddi's sphincter (m-God) treated by endoscopic papillectomy.
  • We herein report a case of early stage ampullary cancer, treated by endoscopic papillectomy, in which tumor extension was confined to the mucosa and adjacent epithelium of the glands in Oddi's sphincter.
  • A 77-year-old man underwent screening esophagogastroduodenoscopy, which revealed a mass in the papilla of Vater, which was well-differentiated adenocarcinoma as proven by biopsy.
  • [MeSH-major] Ampulla of Vater. Carcinoma / surgery. Common Bile Duct Neoplasms / surgery. Duodenoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21088347.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


57. Cho EY, Kim TH, Park SD, Yun KJ, Choi SC, Kim HC, Nah YH: Acral metastasis in a patient with ampullary carcinoma. Korean J Intern Med; 2007 Mar;22(1):55-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acral metastasis in a patient with ampullary carcinoma.
  • Although skin metastasis from a malignant tumor of an internal organ usually occurs at an advanced disease stage, there has been no prior report of a cutaneous acral metastasis from ampullary carcinoma to date.
  • We report a 71-year old male patient with cutaneous metastasis from an ampullary adenocarcinoma.
  • The patient had a history of pylorus preserving pancreaticoduodenectomy for carcinoma of the ampulla of Vater two years prior to presentation.
  • This case illustrates that cutaneous metastasis from ampullary carcinoma has a poor prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater / pathology. Common Bile Duct Neoplasms / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1966 Feb;19(2):162-8 [5948332.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):875-82 [15223956.001]
  • [Cites] J Cutan Pathol. 2004 Jul;31(6):419-30 [15186430.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1176-83 [14654474.001]
  • [Cites] Hepatogastroenterology. 2003 Jan-Feb;50(49):275-7 [12630040.001]
  • [Cites] Cutis. 2002 Oct;70(4):230-2 [12403315.001]
  • [Cites] Clin Geriatr Med. 2002 Feb;18(1):1-19, v [11913734.001]
  • [Cites] Arch Dermatol. 1972 Jun;105(6):862-8 [5030236.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):359-67 [15725805.001]
  • [Cites] Ann Pathol. 2004 Sep;24(4):312-8 [15567946.001]
  • [Cites] Ann Surg. 1998 Jul;228(1):87-94 [9671071.001]
  • [Cites] J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):228-36 [8335743.001]
  • [Cites] J Am Acad Dermatol. 1992 Jul;27(1):117-8 [1320059.001]
  • [Cites] Cutis. 1987 Feb;39(2):119-21 [3829718.001]
  • (PMID = 17427649.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2687605
  •  go-up   go-down


58. Ohno T, Koguchi H, Miura A, Tanaka Y, Endo M, Matsunaga S, Hasegawa I, Kato A, Tokuda Y, Sakakibara K: [A case of advanced ampullary carcinoma successfully resected after primary chemotherapy with s-1 and gemcitabine]. Gan To Kagaku Ryoho; 2009 Jun;36(6):999-1002
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced ampullary carcinoma successfully resected after primary chemotherapy with s-1 and gemcitabine].
  • He was diagnosed as having advanced ampullary carcinoma(T4 N0 H1, Stage IV b).
  • This is a very instructive case for developing effective chemotherapy options to treat biliary tract cancers involving ampullary carcinoma.
  • [MeSH-major] Ampulla of Vater. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Duodenal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542724.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


59. Hsu HP, Shan YS, Lai MD, Lin PW: Osteopontin-positive infiltrating tumor-associated macrophages in bulky ampullary cancer predict survival. Cancer Biol Ther; 2010 Jul 15;10(2):144-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin-positive infiltrating tumor-associated macrophages in bulky ampullary cancer predict survival.
  • PURPOSE: Tumor-associated macrophages (TAMs) promote cancer cell proliferation and distant metastases.
  • Osteopontin (OPN) is overexpressed in several human cancer cells and in TAMs.
  • Therefore, we set out to determine the role of OPN-expressing macrophages in cancer.
  • RESULTS: In 100 ampullary cancers, diffuse cytoplasmic positivity for OPN was found in infiltrating TAMs in 36 patients and marginal TAMs in 32 patients; OPN(+) macrophages were absent in 32 patients.
  • Expression patterns of OPN in TAMs were associated with pancreatic invasion, tumor stage, TNM stage, lymphovascular invasion and recurrence with peritoneal carcinomatosis.
  • Macrophage-associated cytokine expression in ampullary cancer cells was also assessed; levels of macrophage migration inhibitory factor (MIF) in cancer cells were higher than in normal duodenal mucosa.
  • EXPERIMENTAL DESIGN: Specimens from ampullary cancer patients at National Cheng Kung University Hospital were collected for immunohistochemistry.
  • CONCLUSIONS: Expression of OPN and location of TAMs in bulky ampullary cancer predict recurrence.
  • In addition, cytoplasmic staining of MIF is enhanced in ampullary cancer cells.
  • [MeSH-major] Adenocarcinoma / pathology. Ampulla of Vater / pathology. Biomarkers, Tumor / metabolism. Common Bile Duct Neoplasms / pathology. Macrophage Migration-Inhibitory Factors / metabolism. Macrophages / metabolism. Osteopontin / metabolism. RNA, Neoplasm / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495367.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Macrophage Migration-Inhibitory Factors; 0 / RNA, Neoplasm; 106441-73-0 / Osteopontin
  •  go-up   go-down


60. Roggin KK, Yeh JJ, Ferrone CR, Riedel E, Gerdes H, Klimstra DS, Jaques DP, Brennan MF: Limitations of ampullectomy in the treatment of nonfamilial ampullary neoplasms. Ann Surg Oncol; 2005 Dec;12(12):971-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limitations of ampullectomy in the treatment of nonfamilial ampullary neoplasms.
  • BACKGROUND: Pancreaticoduodenectomy (PD) is the standard surgical management of invasive ampullary neoplasms.
  • METHODS: We identified 140 consecutive cases of nonfamilial ampullary neoplasms from our prospective institutional database over a 7-year period (1996-2003).
  • AMP was converted to PD because of the extent of disease in three and an intraoperative diagnosis of invasive cancer in five patients.
  • Intraoperative frozen section had a diagnostic accuracy of 84%; two cases of high-grade dysplasia and invasive cancer were missed.
  • Patients with invasive cancer treated by AMP had a decreased recurrence-free and disease-specific survival compared with those treated by PD.
  • Although both vascular invasion and tumor stage independently predicted lymphatic metastases, both were limited by their sensitivity.
  • CONCLUSIONS: The reduced morbidity and mortality of AMP makes this the preferred treatment for benign lesions of the ampulla.
  • [MeSH-major] Ampulla of Vater / surgery. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2005 Dec;12(12):955-6 [16228813.001]
  • (PMID = 16244798.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Woo SM, Ryu JK, Lee SH, Lee WJ, Hwang JH, Yoo JW, Park JK, Kang GH, Kim YT, Yoon YB: Feasibility of endoscopic papillectomy in early stage ampulla of Vater cancer. J Gastroenterol Hepatol; 2009 Jan;24(1):120-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of endoscopic papillectomy in early stage ampulla of Vater cancer.
  • BACKGROUND AND AIM: Although endoscopic papillectomy has been attempted in early stage ampullary cancer (pTis, T1), its curative role and indications remain uncertain.
  • METHODS: We performed a retrospective analysis of clinical and histopathological data of 216 patients with ampullary cancer between 1991 and 2006.
  • RESULTS: No tumor in pTis stage had metastasized to lymph nodes and only 9% of tumors in pT1 had metastasized.
  • Cases with early stage ampullary cancer of less than 2 cm with a well-differentiated histology and no angiolymphatic invasion (n = 13) showed no lymph node metastasis and no recurrence during a median follow up of 35.9 months.
  • CONCLUSION: Endoscopic papillectomy can be adopted as a viable alternative to surgery in patients with early stage ampullary cancer of less than 2 cm in size and with a well-differentiated histology.
  • [MeSH-major] Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery. Endoscopy, Digestive System

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19032444.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down






Advertisement